Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
| Condition(s) | IgA Nephropathy |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN). |
| Who can participate | Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Biohaven Therapeutics Ltd. |
| Locations | Farmington, Connecticut, United States; Miami Lakes, Florida, United States; Miami Lakes, Florida, United States; Orlando, Florida, United States; Pembroke Pines, Florida, United States; Lawrenceville, Georgia, United States (+9 more sites) |
| Start date | 2025-07-30 |
| NCT ID | NCT07054684 |
| Official listing | https://clinicaltrials.gov/study/NCT07054684 |